Clinical Trial: Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology
Brief Summary: To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: September 11, 2005
Date Started: February 2005
Date Completion:
Last Updated: March 14, 2007
Last Verified: March 2007